We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
-15.82%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.52B
AUM Growth
-$38.2M
Cap. Flow
+$249M
Cap. Flow %
16.37%
Top 10 Hldgs %
48.92%
Holding
59
New
7
Increased
23
Reduced
11
Closed
8

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$52.1M
2
NUVB icon
Nuvation Bio
NUVB
+$45M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$39.3M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$32.3M
5
NRIX icon
Nurix Therapeutics
NRIX
+$27.6M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$65.8M
2
KROS icon
Keros Therapeutics
KROS
+$28.1M
3
SAGE
Sage Therapeutics
SAGE
+$16.9M
4
ENTA icon
Enanta Pharmaceuticals
ENTA
+$14.1M
5
CRNX
Crinetics Pharmaceuticals
CRNX
+$9.75M

Sector Composition

Rank Sector Weight
1 Healthcare 95.07%
2 Miscellaneous 4.93%
3 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KROS icon
26
Keros Therapeutics
KROS
$213M
$20.4M 1.34%
739,528
-640,778
-46% -$28.1M
CRNX
27
DELISTED
Crinetics Pharmaceuticals
CRNX
$19.6M 1.29%
1,053,000
-488,715
-32% -$9.75M
KALV
28
DELISTED
KalVista Pharmaceuticals
KALV
$17.9M 1.18%
1,824,000
+94,243
+5% +$1.04M
DICE
29
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$16.2M 1.06%
1,042,900
-207,100
-17% -$3.56M
INZY
30
DELISTED
Inozyme Pharma
INZY
$15.5M 1.02%
+3,250,000
New +$14.1M
SDGR icon
31
Schrodinger
SDGR
$1.79B
$14.8M 0.98%
+562,000
New +$15.1M
ABOS icon
32
Acumen Pharmaceuticals
ABOS
$189M
$14.6M 0.96%
3,100,000
+500,902
+19% +$1.88M
ANAB icon
33
AnaptysBio
ANAB
$1.61B
$13.7M 0.9%
672,569
+113,787
+20% +$2.52M
VRDN icon
34
Viridian Therapeutics
VRDN
$2.54B
$13.5M 0.89%
1,170,290
– –
ACET icon
35
Adicet Bio
ACET
$84.7M
$13M 0.86%
+55,752
New +$12.2M
JNCE
36
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$12.9M 0.85%
4,259,653
– –
SLN
37
Silence Therapeutics
SLN
$777M
$11.3M 0.74%
951,580
– –
RLMD icon
38
Relmada Therapeutics
RLMD
$450M
$9.49M 0.62%
500,000
+397,883
+390% +$8.68M
HOOK
39
DELISTED
HOOKIPA Pharma
HOOK
$8.21M 0.54%
503,600
– –
IPSC icon
40
Century Therapeutics
IPSC
$337M
$7.77M 0.51%
924,641
-1,828
-0.2% -$17.9K
DNTH icon
41
Dianthus Therapeutics
DNTH
$5.73B
$6.43M 0.42%
334,938
– –
ASMB icon
42
Assembly Biosciences
ASMB
$519M
$6.3M 0.41%
250,000
– –
SAGE
43
DELISTED
Sage Therapeutics
SAGE
$5.55M 0.36%
171,800
-503,200
-75% -$16.9M
PASG icon
44
Passage Bio
PASG
$15.6M
$5.47M 0.36%
116,000
-52,750
-31% -$2.46M
GHRS icon
45
GH Research
GHRS
$1.9B
$4.98M 0.33%
499,400
– –
FULC icon
46
Fulcrum Therapeutics
FULC
$289M
$4.9M 0.32%
1,000,000
+350,000
+54% +$3.42M
GRTS
47
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$4.16M 0.27%
1,720,000
-1,265,729
-42% -$3.32M
TNYA icon
48
Tenaya Therapeutics
TNYA
$147M
$2.72M 0.18%
483,836
-63,087
-12% -$510K
PTGX icon
49
PUT
Protagonist Therapeutics
PTGX
$9.24B
$2.06M 0.14%
260,500
+112,200
+76% +$1.36M
ATYR
50
aTyr Pharma
ATYR
$37.7M
$823K 0.05%
290,844
-737,671
-72% -$2.67M
1
2
3

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Deep Track Capital held 59 positions worth $1.52B, down 2.4% from $1.56B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Deep Track Capital deployed $249M of net new capital in Q2 2022, opening 7 new positions and adding to 23 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 654,365 shares worth $54.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $28.1M trimmed.

  • Deep Track Capital's largest Q2 2022 buy was BioMarin Pharmaceuticals: 654,365 shares worth $54.2M.
  • Deep Track Capital added most to Nuvation Bio in Q2 2022, an estimated $45M increase.
  • Deep Track Capital's biggest Q2 2022 reduction was Keros Therapeutics, cutting an estimated $28.1M.
  • Deep Track Capital fully exited Alnylam Pharmaceuticals in Q2 2022, selling an estimated $65.8M.
  • Deep Track Capital's ten largest holdings make up 49% of its $1.52B portfolio in Q2 2022.
  • Deep Track Capital opened 7 new positions and closed 8 in Q2 2022.
  • Deep Track Capital's portfolio value fell 2.4% quarter-over-quarter to $1.52B.

Based on Deep Track Capital's 13F filing for Q2 2022, filed 12 Aug 2022.